Reversine: Protocol Parameters and Workflow Guidance

What This Product Solves

Reversine (SKU A3760) is a chemically defined small molecule inhibitor targeting Aurora kinases A, B, and C, all of which are central regulators of mitotic progression and cell cycle control. By inhibiting these serine/threonine kinases, Reversine facilitates the study of mitotic checkpoint integrity, cell cycle arrest, and apoptosis induction in cancer cells. Its nanomolar potency (IC50: Aurora A – 150 nM, B – 500 nM, C – 400 nM) enables precise modulation of the Aurora kinase signaling pathway—an essential tool for dissecting cancer cell proliferation inhibition and understanding mechanisms of resistance or checkpoint failure in tumor models (product_spec). This compound is primarily recommended for in vitro and in vivo research in oncology, with demonstrated compatibility in cervical cancer model systems and established protocols for dedifferentiation studies using murine myoblasts.

For a discussion on advanced mitotic checkpoint targeting strategies using Reversine, see "Reversine and the Future of Mitotic Checkpoint Intervention", which provides actionable insights on leveraging cell cycle vulnerabilities. For practical workflow setup and troubleshooting, refer to "Reversine: Practical Guide for Aurora Kinase Inhibition Workflows".

Protocol Parameters

• assay | IC50 (Aurora A): 150 nM | applicability: in vitro kinase assays and cellular studies targeting mitotic entry and centrosome functions | rationale: enables selective inhibition of Aurora A, critical for centrosome maturation and separation in dividing cancer cells | source_type: product_spec
• assay | Solubility in DMSO: ≥19.65 mg/mL | applicability: preparation of concentrated stock solutions for cell-based or biochemical assays | rationale: ensures consistent dosing and reproducibility in experiments targeting Aurora kinase signaling | source_type: product_spec
• assay | Storage: -20°C (solid form) | applicability: long-term preservation of compound stability prior to use in research workflows | rationale: prevents degradation and loss of inhibitor potency; aliquot and minimize freeze-thaw cycles | source_type: product_spec
• assay | Solubility in Ethanol: ≥6.69 mg/mL (with warming/ultrasonic aid) | applicability: alternative solvent for applications where DMSO may interfere | rationale: enables flexible solvent choice for assay compatibility | source_type: product_spec
• assay | Working Solution Usage: Immediate, avoid long-term storage | applicability: all experimental protocols employing Reversine in solution | rationale: solutions are unstable with time; prepare fresh to maintain activity | source_type: product_spec

Workflow Setup and QC Checklist

• Confirm compound identity and batch before use; verify storage at -20°C and check for signs of degradation (e.g., discoloration, precipitate).
• Prepare concentrated stocks in DMSO at ≥19.65 mg/mL. Use ethanol (≥6.69 mg/mL, with gentle warming and ultrasonic treatment) if DMSO is incompatible with assay system (product_spec).
• Filter-sterilize solutions if required for cell culture applications. Avoid extended storage of working solutions; freshly prepare aliquots for each experiment.
• For cell-based assays: titrate Reversine to determine optimal concentration for Aurora kinase inhibition, considering IC50 guidance and cell line sensitivity (workflow recommendation).
• Include appropriate vehicle (DMSO/ethanol) controls and, where possible, positive controls for cell cycle arrest or apoptosis.
• Document all handling, aliquoting, and experimental steps for reproducibility and compliance.

Common Failure Modes and Fixes

• Poor solubility in aqueous media: Reversine is insoluble in water; always dissolve in DMSO or ethanol as specified. If precipitation occurs upon dilution, warm gently and vortex. Confirm complete dissolution before use (product_spec).
• Loss of activity due to solution storage: Do not store working solutions for extended periods—prepare fresh aliquots immediately prior to use to avoid potency loss (product_spec).
• Cell toxicity unrelated to Aurora kinase inhibition: High concentrations of DMSO/ethanol or compound degradation may cause off-target effects. Maintain vehicle concentration below cytotoxic thresholds and monitor cell health regularly (workflow recommendation).
• Batch-to-batch variability: Validate each new batch with a pilot assay; document lot numbers and QC data for traceability.

Scope and Limitations

Reversine is intended for scientific research use only and is not for diagnostic or clinical applications. Its validated use cases are restricted to in vitro and in vivo research on mitotic regulation, cancer cell proliferation inhibition, apoptosis induction in cancer cells, and studies of the Aurora kinase signaling pathway. The compound’s performance and safety profile are defined by its product specification; no direct clinical or diagnostic applications are supported. Solubility constraints require careful solvent selection and handling. The product’s stability is only guaranteed under specified storage conditions; deviation may compromise research outcomes (product_spec).

Conclusion

Reversine offers researchers a potent, well-characterized Aurora kinase inhibitor suited for dissecting mitotic checkpoints and apoptosis mechanisms in cancer biology. Adherence to recommended protocol parameters, solvent usage, and storage guidelines is critical for experimental success. For further practical guidance and troubleshooting strategies, consult established internal resources. For product details and ordering, visit APExBIO's Reversine page.